Palvella Therapeutics Inc Ne

CUSIP 697947109COMPVLAQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

14.6%

Max % of class reported

Institutional Holders

174

13F filers (latest quarter)

14 filings · latest Feb 17, 2026

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	Feb 17, 2026	First Light Asset Management, LLC	13G	7.5%	887.0K	SEC
2	Feb 17, 2026	Biotechnology Value Fund L P	13G/A	7.1%	879.0K	SEC
3	Feb 13, 2026	Frazier Life Sciences Public Fund, L.P.	13G/A	6.0%	706.4K	SEC
4	Nov 14, 2025	Biotechnology Value Fund L P	13G/A	10.0%	1.18M	SEC
5	Nov 13, 2025	Suvretta Capital Management, LLC	13G/A	7.4%	822.4K	SEC
6	Aug 14, 2025	Samsara Biocapital, L.P.	13G/A	3.1%	339.7K	SEC
7	Aug 14, 2025	Frazier Life Sciences Public Fund, L.P.	13G/A	4.9%	545.5K	SEC
8	May 15, 2025	Frazier Life Sciences Public Fund, L.P.	13G/A	6.3%	690.0K	SEC
9	Jan 8, 2025	Frazier Life Sciences Public Fund, L.P.	13G	11.0%	575.9K	SEC
10	Dec 20, 2024	Kaupinen Wes	13D	14.6%	—	SEC

See the full Schedule 13D/13G history for Palvella Therapeutics Inc Ne.

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Suvretta Capital Management, LLC	1.15M	$143.78M
2	First Light Asset Management, LLC	980.8K	$122.25M
3	Bvf Inc/Il	961.0K	$119.79M
4	Frazier Life Sciences Management, L.P.	882.4K	$109.99M
5	Blackrock, Inc.	686.9K	$85.62M
6	Jennison Associates LLC	640.6K	$79.85M
7	State Street Corp	459.0K	$57.21M
8	Federated Hermes, Inc.	433.0K	$53.98M
9	Frontier Capital Management Co LLC	374.0K	$46.62M
10	Woodline Partners LP	317.5K	$39.58M